1655501-53-3
Chemical Structure
Fremanezumab
Synonym(s): TEV-48125; LBR-101; PF-04427429; RN-307
- CAS No.: 1655501-53-3
- Formula:N/A
- Molecular Weight:(145.5 kDa)
IUPAC Name: (1R,7aR)-7-((((R)-2,3-dihydroxy-2-((S)-1-hydroxyethyl)-3-methylbutanoyl)oxy)methyl-d2)-2,3,5,7a-tetrahydro-1H-pyrrolizin-1-yl-1-d (Z)-2-methylbut-2-enoate
SMILES: [Fremanezumab]
Biological Activity: Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Fremanezumab | 95.00% | Fremanezumab (TEV-48125) is a humanized lgG2 monoclonal antibody that selectively and potently binds to calcitonin gene related peptide (CGRp) (IC50 values = 7.943 nM). Fremanezumab binds to mouse CGRP with an IC50 value of 19.6 nM. Fremanezumab counteracts anti-inflammatory effects of CGRP in vitro, including CGRP-mediated inhibition of LPS (HY-D1056)-induced microglial activation. Fremanezumab selectively inhibits the activation of Aδ meningeal nociceptors by cortical spreading depression (CSD) in rats. Fremanezumab can be used for the study of inflammation and chronic migraine. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Pistolesi A, et al. The anti-CGRP mAb Fremanezumab reverts the anti-inflammatory effects of CGRP in vitro but does not alter disease evolution in a mouse model of progressive multiple sclerosis. Eur J Pharmacol. 2025 May 15;995:177415. [Content Brief]
- [2]. Grell AS, et al. Fremanezumab inhibits vasodilatory effects of CGRP and capsaicin in rat cerebral artery - Potential role in conditions of severe vasoconstriction. Eur J Pharmacol. 2019 Dec 1;864:172726. [Content Brief]
- [3]. Melo-Carrillo A, et al. Fremanezumab-A Humanized Monoclonal Anti-CGRP Antibody-Inhibits Thinly Myelinated (Aδ) But Not Unmyelinated (C) Meningeal Nociceptors. J Neurosci. 2017 Nov 1;37(44):10587-10596. [Content Brief]
Keywords
